Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

June 10, 2019

Study Completion Date

June 15, 2019

Conditions
Type 2 Diabetes MellitusInsulin Resistance
Interventions
DRUG

Metformin

background drug

DRUG

saxagliptin

background drug

DRUG

AZD9668

study drug

DRUG

placebo

placebo for AZD9668 to be added to background drugs

Trial Locations (1)

15224

Allegheny Health Network, Pittsburgh

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

University of Pittsburgh

OTHER

collaborator

University of South Florida

OTHER

collaborator

AstraZeneca

INDUSTRY

lead

Nick Giannoukakis, PhD

OTHER